Baidu
map

论文与基金

订阅

MedSci主页 / 所有栏目 / 论文与基金

RNA修饰创新研究设计-m6A甲基化的测序方法？

2021-09-09 MedSci原创 MedSci原创

研究设计RNA修师创新研究
关注

RNA修饰创新研究设计-问题2

更多科研课程：点击下方图片

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1647777, encodeId=79fb164e77708, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Fri Oct 29 05:03:28 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057471, encodeId=bbaf205e47134, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Aug 03 14:03:28 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286034, encodeId=4ef91286034c0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569402, encodeId=bc801569402aa, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=)]
    2021-10-29 kcb077

    #m6A#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1647777, encodeId=79fb164e77708, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Fri Oct 29 05:03:28 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057471, encodeId=bbaf205e47134, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Aug 03 14:03:28 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286034, encodeId=4ef91286034c0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569402, encodeId=bc801569402aa, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=)]
    2022-08-03 drj2003

    #RNA修饰#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1647777, encodeId=79fb164e77708, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Fri Oct 29 05:03:28 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057471, encodeId=bbaf205e47134, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Aug 03 14:03:28 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286034, encodeId=4ef91286034c0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569402, encodeId=bc801569402aa, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=)]
    2021-09-11 lilianxiang

    #创新#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1647777, encodeId=79fb164e77708, content=<a href='/topic/show?id=ac501119586' target=_blank style='color:#2F92EE;'>#m6A#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11195, encryptionId=ac501119586, topicName=m6A)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e88323484130, createdName=kcb077, createdTime=Fri Oct 29 05:03:28 CST 2021, time=2021-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2057471, encodeId=bbaf205e47134, content=<a href='/topic/show?id=a7d3155507b' target=_blank style='color:#2F92EE;'>#RNA修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15550, encryptionId=a7d3155507b, topicName=RNA修饰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Wed Aug 03 14:03:28 CST 2022, time=2022-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1286034, encodeId=4ef91286034c0, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569402, encodeId=bc801569402aa, content=<a href='/topic/show?id=1c562e42646' target=_blank style='color:#2F92EE;'>#修饰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27426, encryptionId=1c562e42646, topicName=修饰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=29c615505859, createdName=zhangyxzsh, createdTime=Sat Sep 11 05:03:28 CST 2021, time=2021-09-11, status=1, ipAttribution=)]
    2021-09-11 zhangyxzsh

    #修饰#

    0

相关资讯

J Rheumatol：类风湿性关节炎临床试验中的安慰剂反应

过去20年间，RA临床试验中的安慰剂反应有所增加。RA表型的转换、试验设计的改变以及期望偏倚与这种现象有关。

科研日历-偏倚

偏倚种类有哪些？选择偏倚--发生于临床研究招募受试者和随访环节信息偏倚--发生于临床研究的执行环节混杂偏倚--发生于临床研究设计环节什么是偏倚？偏倚是指在流行病学研究的设计、实施或资料分析阶段，由于设计者、操作者的人为因素，在选择观察对象、收集资料、处理数据或解释结果时产生的各种系统误差。相关课程请关注梅斯医学APP！

这样竟然能发Lancet？！样本量92例，6周就出结果……

快来学习一下！

瑞德西韦遭遇患者样本不足，“人民的希望”的研究设计应该反思与修改

早在 2 月 4 日，吉利德的 2843 箱瑞德西韦药物就已经运抵北京，时至今日人们却听到了入组患者太少的消息，“人民的希望”被浇了一头冷水。瑞德西韦是被世界卫生组织认为是目前唯一可能抗击新冠病毒的药物。“人民的希望”是网友对瑞德西韦英文名 Remdesivir 的谐音，也表达了民众对此药的期待。2 月 24 日的新闻发布会上，世界卫生组织总干事高级顾问布鲁斯 · 艾尔沃德（Bruce Ayl

科研日历—终点制定

主要终点制定原则？ 直接与研究目的挂钩 一个研究只有一个主要终点 硬终点更适合作为主要终点 主要终点直接与样本量计算等挂钩 只有主要终点具备RCT一级证据 相关课程请关注梅斯医学APP！

巴豆酰化与肠道菌群代谢的具体关系？

高博士——RNA修饰创新研究设计_提问与回答1

Baidu
map
Baidu
map
Baidu
map